Almirall's 16th Skin Academy Brings Together Leading Experts to Advance Skin Science and Treatment Options in Medical Dermatology
21.3.2025 07:00:00 CET | Business Wire | Press release
Almirall’s 16th Skin Academy is a unique opportunity for collaboration in medical dermatology as it brings together leading experts from across the globe to advance science and innovative approaches for the treatment of skin diseases.The conference focuses on the latest advancements in medical dermatology, including the holistic and personalized treatment of atopic dermatitis and psoriasis.The comprehensive program covers a broad range of skin diseases such as actinic keratosis, androgenetic alopecia, onychomycosis and chronic spontaneous urticaria - advancing the understanding of these diseases and treatment options to support better patient outcomes.
Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16th edition of Skin Academy, a premier conference for healthcare professionals in the field of dermatology. This year's event features a comprehensive program aimed at sharing state-of-the-art scientific knowledge on skin diseases, their treatment, and clinical best practice.
The Skin Academy is a unique opportunity for collaboration, bringing together a broad range of leading experts and clinicians from across the globe to create a network of peers that discuss and learn together to advance the treatment of skin diseases. The event will foster collaboration and co-creation of innovative approaches and solutions to better respond to the unmet needs of the millions of people living with dermatological conditions.
Prof. Dr. Ulrich Mrowietz, from the Psoriasis Center at the University Medical Center Schleswig-Holstein, Campus Kielin Germany said: "deep collaboration across experts is essential for advancing medical dermatology and providing better treatment outcomes for patients. Almirall’s Skin Academy provides a unique platform for practitioners to explore latest scientific advances, clinical practice and discuss a broad range of skin diseases, with an emphasis on holistic, personalized patient care and wellbeing."
The Chief Medical Officer of Almirall, Dr. Volker Koscielny, said: "this is the 16th edition of the Skin Academy, and we are proud to continue to provide a leading platform for exchange and advancement in medical dermatology. Partnering with the dermatology community across Europe is based on our unique focus on medical dermatology and supported by our R&D capabilities as well as our strong collaborations. Skin Academy fosters collaboration and co-creation of innovative approaches and solutions that help the medical dermatology community to better respond to the unmet needs of millions of people living with these conditions."
About Almirall’s Skin Academy
The Skin Academy, initiated and sponsored by Almirall, has become a cornerstone event for healthcare professionals in medical dermatology. Over the years, it has evolved into a key platform for sharing state-of-the-art scientific knowledge and clinical best practices in a wide range of skin diseases that affect millions of people. The event encourages collaboration and the development of new methods and solutions, aiming at addressing the unmet needs of patients and the medical dermatology community. The 16th edition continues this focus and Almirall’s commitment to educational advancement, bringing together over 800 participants, led by international experts, with common interests to create a network to discuss, educate, and learn to advance knowledge in medical dermatology.
About atopic dermatitis
As a highly prevalent and debilitating condition, atopic dermatitis will be a central focus at the conference, with experts offering new insights into its pathophysiology, the role of IL-13, and the importance of advanced treatment protocols. In addition, the discussion will include a comprehensive analysis of efficacy and safety of leading treatments over time, as well as real-world evidence from clinical practice. Another key topic is the dermatologist-patient relationship, which is crucial for treatment success, especially based on the role of shared decision-making in treatment planning.
About psoriasis
Psoriasis will be another focus area for the 16th Skin Academy, and will be addressed in a range of sessions specifically dedicated to biologic treatments. The speakers will address unmet medical needs, the importance of individualized treatment for long-term disease control and share real world evidence showing the effectiveness and safety of targeted IL-23 inhibition, as well as highlighting the importance of striving for patient wellbeing as treatment outcome. Moreover, as difficult-to-treat areas of the skin remain of special importance for patients suffering from psoriasis, current treatment challenges and approaches to address these will be discussed, including advancements in topical treatments and new efficacy data with IL-23 inhibition in psoriasis of the scalp, which affects 40-90% of patients with psoriasis1234.
About Actinic Keratosis
The conference will address the crucial relationship between patients and their physicians, which is essential for treatment success and patient satisfaction, particularly in managing chronic skin diseases. It will highlight the importance of early treatment in actinic keratosis (AK) to prevent its progression to squamous cell carcinoma. Experts will cover advancements in AK treatment, real-world evidence, and the role of patient satisfaction in treatment outcomes.
The conference program further includes topics on other important dermatological conditions, including androgenetic alopecia, onychomycosis, and chronic spontaneous urticaria. The event will also feature poster sessions, clinical case discussions, and Q&A sessions with experts, ensuring an engaging and interactive experience for all participants.
About Almirall
Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients' needs.
Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2024: €990 MM, over 2000 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.
For more information, please visit https://www.almirall.com/
1 Augustin M, Sommer R, Kirsten N, et al. Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. Br J Dermatol. 2019;181:358-365. |
2 Egeberg A, See K, Garrelts A, et al. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20:3. |
3 Merola JF, Li T, Li WQ, et al. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016; 41:486-489. |
4 Sampogna F, Linder D, Piaserico S, et al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol. 2014;94: 411-414. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320758758/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Accertify's Q2 Global Air Travel Fraud Report Finds Fraud Pressure Intensifying Across Middle East and Africa15.7.2026 13:00:00 CEST | Press release
Analysis of nearly 133 million airline booking transactions finds bookings departing from Cairo carried the world's highest fraud rate this quarter, while departure cities across the United States and Australia posted among the lowest fraud rates Accertify, a leading fraud decisioning provider whose Predictive Yes Platform helps merchants say yes to more good customers, more revenue, and more growth, today announced the release of its Global Air Travel Fraud Report: Q2 2026, a quarterly analysis examining how fraud pressure varies across global airline markets based on departure city at time of booking. Based on analysis of 132.9 million airline booking transactions processed between April and June 2026, the report evaluates prevented fraud rates across 537 departure cities that each processed at least 10,000 transactions during the quarter, providing airlines with a data-driven view of where Accertify's Predictive Yes platform intervened most frequently at booking. The Q2 findings rev
Forrester’s 2027 Budget Planning Guides: After A Year Of Caution, Business And Tech Leaders Are Ready To Invest Again15.7.2026 11:00:00 CEST | Press release
While leaders are betting on growth, in the age of AI, spending more is no longer enough According to Forrester’s (Nasdaq: FORR) 2027 Budget Planning Guides, business and technology leaders are approaching 2027 with renewed confidence as they increasingly accept volatility as a permanent feature of the business environment. After a year of more cautious spending, more than 80% of leaders expect their budgets to increase over the next 12 months, with as many as one-quarter anticipating growth of 10% or more. But planning in the age of AI demands more than bigger budgets: Increasing investment without modernizing operating models, strengthening data foundations, and improving AI readiness will only accelerate fragmented data, duplicated work, and technical debt. To realize AI’s full potential, leaders must rethink their strategies and prioritize investments in operational foundations, governance, and experimentation that drive tangible outcomes. This year, optimism is widespread across f
Post-Quantum’s Algorithm - Classic McEliece - Achieves Global ISO Standardization to Protect the World From Quantum Cyber Attack15.7.2026 10:00:00 CEST | Press release
Ultra-secure encryption algorithm added to ISO standard for Asymmetric Ciphers Classic McEliece is first PQC algorithm to achieve global standardization Organisations in 177 ISO member states can now adopt Classic McEliece to remain secure from attack by both classical and quantum computers Governments including Germany and the Netherlands already recommend the highly secure Classic McEliece algorithm due to its unmatched security credentials It’s proven that today’s encryption is vulnerable to attack by a sufficiently mature quantum computer running Shor’s algorithm - a catastrophic event commonly known as Q-Day. Even before such a cryptographically relevant quantum computer emerges it is known that adversaries are stealing encrypted data now, which can be decrypted later - also known as Harvest Now, Decrypt Later (HNDL). Google’s recent use of Artificial Intelligence (AI) to optimise Shor’s algorithm reduces the number of physical qubits required to break today’s encryption, therefor
Thredd Joins The Visa Agentic Ready Programme, Bringing Agent Network Readiness To Issuers Across Europe, Starting With Zilch15.7.2026 09:00:00 CEST | Press release
Thredd, the AI-first issuer processing platform, today announced it has joined the Visa Agentic Ready programme, enabling issuers across Europe to participate in agent-initiated payments without rebuilding their payments infrastructure. Consumer payments platform Zilch will be among the first issuers on the platform to enable agent-initiated payments for its cardholders. As a processor and enabler, Thredd sits at the trust layer of the payments ecosystem. By joining the programme, Thredd is ready to support Visa and its clients as the market moves into agentic commerce. Agentic commerce introduces a new type of payment initiator: An AI agent acting on a cardholder's behalf. The core payments principles do not change. Cardholder permission, issuer approval, authentication and fraud monitoring all still apply. What changes is how trust is established and enforced at the point an agent transacts. Taking a Zilch customer as an example, a cardholder might ask an AI agent to find a product w
Surgerii Robotics Announces First European Installation of the SHURUI® Single-Port Surgical System at Vall d'Hebron University Hospital15.7.2026 09:00:00 CEST | Press release
Surgerii Robotics today announced the first European installation of its SHURUI Single-Port (SP) Surgical System at Vall d'Hebron University Hospital in Barcelona, Spain, one of Europe's leading academic medical centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713209503/en/ The first pediatric procedure performed with the SHURUI SP system was a nephroureterectomy on a twelve-year-old boy whose kidney and ureter had become infected and non-functional due to multiple stones. The SHURUI SP system is CE-marked for adult and pediatric use, making it the only CE-marked single-port robotic surgical system currently indicated for pediatric procedures in Europe. The installation marks an important milestone in the international expansion of Surgerii Robotics and the introduction of the technology into a major European reference center. As part of this collaboration, Vall d'Hebron University Hospital has become the first hos
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom